Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.

Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.

Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.

2.

The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models.

Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D.

Mol Cancer Ther. 2019 Oct 3. pii: molcanther.0019.2019. doi: 10.1158/1535-7163.MCT-19-0019. [Epub ahead of print]

PMID:
31582533
3.

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.

Wickstroem K, Hagemann UB, Kristian A, Ellingsen C, Sommer A, Ellinger-Ziegelbauer H, Wirnitzer U, Hagelin EM, Larsen A, Smeets R, Bjerke RM, Karlsson J, Ryan OB, Wengner AM, Linden L, Mumberg D, Cuthbertson AS.

Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):410-422. doi: 10.1016/j.ijrobp.2019.06.2508. Epub 2019 Jun 27.

PMID:
31255687
4.

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.

Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V, Wickstroem K, Schatz CA, Kneip C, Golfier S, Smeets R, Uran S, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Mumberg D, Ziegelbauer K, Cuthbertson AS.

Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476. Epub 2019 May 7.

PMID:
31064781
5.

Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.

Wickstroem K, Hagemann UB, Cruciani V, Wengner AM, Kristian A, Ellingsen C, Siemeister G, Bjerke RM, Karlsson J, Ryan OB, Linden L, Mumberg D, Ziegelbauer K, Cuthbertson AS.

J Nucl Med. 2019 Sep;60(9):1293-1300. doi: 10.2967/jnumed.118.223701. Epub 2019 Mar 8.

6.

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.

Sugawara T, Baumgart SJ, Nevedomskaya E, Reichert K, Steuber H, Lejeune P, Mumberg D, Haendler B.

Int J Cancer. 2019 Sep 1;145(5):1382-1394. doi: 10.1002/ijc.32242. Epub 2019 Mar 23.

7.

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Grünewald S, Politz O, Bender S, Héroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K.

Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13.

8.

Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.

Huynh H, Ong R, Goh KY, Lee LY, Puehler F, Scholz A, Politz O, Mumberg D, Ziegelbauer K.

Int J Oncol. 2019 Mar;54(3):1123-1133. doi: 10.3892/ijo.2019.4693. Epub 2019 Jan 23.

PMID:
30747223
9.

Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.

Nguyen D, Lemos C, Wortmann L, Eis K, Holton SJ, Boemer U, Moosmayer D, Eberspaecher U, Weiske J, Lechner C, Prechtl S, Suelzle D, Siegel F, Prinz F, Lesche R, Nicke B, Nowak-Reppel K, Himmel H, Mumberg D, von Nussbaum F, Nising CF, Bauser M, Haegebarth A.

J Med Chem. 2019 Jan 24;62(2):928-940. doi: 10.1021/acs.jmedchem.8b01606. Epub 2019 Jan 9.

PMID:
30563338
10.

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo.

Siemeister G, Mengel A, Fernández-Montalván AE, Bone W, Schröder J, Zitzmann-Kolbe S, Briem H, Prechtl S, Holton SJ, Mönning U, von Ahsen O, Johanssen S, Cleve A, Pütter V, Hitchcock M, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D.

Clin Cancer Res. 2019 Feb 15;25(4):1404-1414. doi: 10.1158/1078-0432.CCR-18-0628. Epub 2018 Nov 14.

PMID:
30429199
11.

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, Mumberg D, Ziegelbauer K, Schatz CA.

Oncotarget. 2018 Sep 25;9(75):34103-34121. doi: 10.18632/oncotarget.26135. eCollection 2018 Sep 25.

12.

Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells.

Regan JL, Schumacher D, Staudte S, Steffen A, Haybaeck J, Keilholz U, Schweiger C, Golob-Schwarzl N, Mumberg D, Henderson D, Lehrach H, Regenbrecht CRA, Schäfer R, Lange M.

Cell Rep. 2017 Dec 5;21(10):2813-2828. doi: 10.1016/j.celrep.2017.11.025.

13.

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.

Lücking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, Briem H, Terebesi I, Meyer K, Prelle K, Denner K, Bömer U, Schäfer M, Eis K, Valencia R, Ince S, von Nussbaum F, Mumberg D, Ziegelbauer K, Klebl B, Choidas A, Nussbaumer P, Baumann M, Schultz-Fademrecht C, Rühter G, Eickhoff J, Brands M.

ChemMedChem. 2017 Nov 8;12(21):1776-1793. doi: 10.1002/cmdc.201700447. Epub 2017 Oct 16.

14.

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A.

Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31.

15.

Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.

Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, Keng Magdalene KH, Tan SH, Lange M, Tan SY, Mumberg D, Lim ST, Ziegelbauer K, Liu N.

Cancer Cell. 2017 Jan 9;31(1):64-78. doi: 10.1016/j.ccell.2016.12.003.

16.

BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.

Santag S, Siegel F, Wengner AM, Lange C, Bömer U, Eis K, Pühler F, Lienau P, Bergemann L, Michels M, von Nussbaum F, Mumberg D, Petersen K.

Cancer Lett. 2017 Apr 1;390:21-29. doi: 10.1016/j.canlet.2016.12.029. Epub 2016 Dec 31.

17.

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.

Politz O, Siegel F, Bärfacker L, Bömer U, Hägebarth A, Scott WJ, Michels M, Ince S, Neuhaus R, Meyer K, Fernández-Montalván AE, Liu N, von Nussbaum F, Mumberg D, Ziegelbauer K.

Int J Cancer. 2017 Jan 15;140(2):449-459. doi: 10.1002/ijc.30457. Epub 2016 Oct 20.

18.

Acetyl-CoA carboxylase inhibitors attenuate WNT and Hedgehog signaling and suppress pancreatic tumor growth.

Petrova E, Scholz A, Paul J, Sturz A, Haike K, Siegel F, Mumberg D, Liu N.

Oncotarget. 2017 Jul 25;8(30):48660-48670. doi: 10.18632/oncotarget.12650.

19.

Functional and Structural Characterization of Bub3·BubR1 Interactions Required for Spindle Assembly Checkpoint Signaling in Human Cells.

Prinz F, Puetter V, Holton SJ, Andres D, Stegmann CM, Kwiatkowski D, Prechtl S, Petersen K, Beckmann G, Kreft B, Mumberg D, Fernández-Montalván A.

J Biol Chem. 2016 May 20;291(21):11252-67. doi: 10.1074/jbc.M115.702142. Epub 2016 Mar 30.

20.

Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524.

Baron AP, von Schubert C, Cubizolles F, Siemeister G, Hitchcock M, Mengel A, Schröder J, Fernández-Montalván A, von Nussbaum F, Mumberg D, Nigg EA.

Elife. 2016 Feb 17;5. pii: e12187. doi: 10.7554/eLife.12187.

21.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.

Wengner AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Raschke M, Frisk AL, von Ahsen O, Michels M, Kreft B, von Nussbaum F, Brands M, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2016 Apr;15(4):583-92. doi: 10.1158/1535-7163.MCT-15-0500. Epub 2016 Feb 1.

22.

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.

Sugawara T, Lejeune P, Köhr S, Neuhaus R, Faus H, Gelato KA, Busemann M, Cleve A, Lücking U, von Nussbaum F, Brands M, Mumberg D, Jung K, Stephan C, Haendler B.

Oncotarget. 2016 Feb 2;7(5):6015-28. doi: 10.18632/oncotarget.6864.

23.

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A.

Neoplasia. 2013 Oct;15(10):1161-71.

24.

BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.

Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, Scott WJ, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2013 Nov;12(11):2319-30. doi: 10.1158/1535-7163.MCT-12-0993-T. Epub 2013 Oct 29.

25.

Characterization of novel MPS1 inhibitors with preclinical anticancer activity.

Jemaà M, Galluzzi L, Kepp O, Senovilla L, Brands M, Boemer U, Koppitz M, Lienau P, Prechtl S, Schulze V, Siemeister G, Wengner AM, Mumberg D, Ziegelbauer K, Abrieu A, Castedo M, Vitale I, Kroemer G.

Cell Death Differ. 2013 Nov;20(11):1532-45. doi: 10.1038/cdd.2013.105. Epub 2013 Aug 9.

26.

Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.

Suominen MI, Rissanen JP, Käkönen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Käkönen SM, Scholz A.

J Natl Cancer Inst. 2013 Jun 19;105(12):908-16. doi: 10.1093/jnci/djt116. Epub 2013 May 16.

PMID:
23682134
27.

BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.

Siemeister G, Lücking U, Wengner AM, Lienau P, Steinke W, Schatz C, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2012 Oct;11(10):2265-73. doi: 10.1158/1535-7163.MCT-12-0286. Epub 2012 Jul 19.

28.

Antiproliferative effects of DNA methyltransferase 3B depletion are not associated with DNA demethylation.

Hagemann S, Kuck D, Stresemann C, Prinz F, Brueckner B, Mund C, Mumberg D, Sommer A.

PLoS One. 2012;7(5):e36125. doi: 10.1371/journal.pone.0036125. Epub 2012 May 1.

29.

Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.

Wellenreuther R, Keppler D, Mumberg D, Ziegelbauer K, Lessl M.

Drug Discov Today. 2012 Nov;17(21-22):1242-8. doi: 10.1016/j.drudis.2012.04.004. Epub 2012 Apr 12. Review.

PMID:
22521665
30.

Isolation of more potent oncolytic paramyxovirus by bioselection.

Beier R, Hermiston T, Mumberg D.

Gene Ther. 2013 Jan;20(1):102-11. doi: 10.1038/gt.2012.13. Epub 2012 Feb 23.

PMID:
22357510
31.

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo.

Strube A, Suominen MI, Rissanen JP, Mumberg D, Klar U, Halleen JM, Käkönen SM.

Osteoporos Int. 2011 Nov;22(11):2887-93. doi: 10.1007/s00198-010-1486-9. Epub 2010 Nov 23.

PMID:
21104229
32.

Characterization of a new renal cell carcinoma bone metastasis mouse model.

Strube A, Stepina E, Mumberg D, Scholz A, Hauff P, Käkönen SM.

Clin Exp Metastasis. 2010 May;27(5):319-30. doi: 10.1007/s10585-010-9329-9. Epub 2010 May 5.

PMID:
20443133
33.

Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.

Puhlmann J, Puehler F, Mumberg D, Boukamp P, Beier R.

Oncogene. 2010 Apr 15;29(15):2205-16. doi: 10.1038/onc.2009.507. Epub 2010 Jan 25.

PMID:
20101224
34.

Oncogenes meet metabolism. From deregulated genes to a broader understanding of tumour physiology. Preface.

Riefke B, Mumberg D, Kroemer G, Keun H, Petersen K, Steger-Hartmann T.

Ernst Schering Found Symp Proc. 2007;(4):V-VII. No abstract available.

PMID:
18811050
35.

Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.

Pühler F, Willuda J, Puhlmann J, Mumberg D, Römer-Oberdörfer A, Beier R.

Gene Ther. 2008 Mar;15(5):371-83. doi: 10.1038/sj.gt.3303095. Epub 2008 Jan 17.

PMID:
18200068
36.

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.

Santamaria A, Neef R, Eberspächer U, Eis K, Husemann M, Mumberg D, Prechtl S, Schulze V, Siemeister G, Wortmann L, Barr FA, Nigg EA.

Mol Biol Cell. 2007 Oct;18(10):4024-36. Epub 2007 Aug 1.

37.

TT virus-derived apoptosis-inducing protein induces apoptosis preferentially in hepatocellular carcinoma-derived cells.

Kooistra K, Zhang YH, Henriquez NV, Weiss B, Mumberg D, Noteborn MH.

J Gen Virol. 2004 Jun;85(Pt 6):1445-50.

PMID:
15166427
38.

Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis.

Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D, Noteborn MH.

J Biol Chem. 2003 Jul 25;278(30):27729-36. Epub 2003 May 16.

39.

A tumor-specific kinase activity regulates the viral death protein Apoptin.

Rohn JL, Zhang YH, Aalbers RI, Otto N, Den Hertog J, Henriquez NV, Van De Velde CJ, Kuppen PJ, Mumberg D, Donner P, Noteborn MH.

J Biol Chem. 2002 Dec 27;277(52):50820-7. Epub 2002 Oct 21.

40.

Vector systems for heterologous expression of proteins in Saccharomyces cerevisiae.

Funk M, Niedenthal R, Mumberg D, Brinkmann K, Rönicke V, Henkel T.

Methods Enzymol. 2002;350:248-57. No abstract available.

PMID:
12073316
41.

Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.

Beck-Engeser GB, Monach PA, Mumberg D, Yang F, Wanderling S, Schreiber K, Espinosa R 3rd, Le Beau MM, Meredith SC, Schreiber H.

J Exp Med. 2001 Aug 6;194(3):285-300.

42.
43.

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8633-8. Erratum in: Proc Natl Acad Sci U S A 2000 Feb 29;97(5):2397.

44.
45.

Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation.

Mumberg D, Wick M, Bürger C, Haas K, Funk M, Müller R.

Nucleic Acids Res. 1997 Jun 1;25(11):2098-105.

46.

Use of conditional promoters for expression of heterologous proteins in Saccharomyces cerevisiae.

Rönicke V, Graulich W, Mumberg D, Müller R, Funk M.

Methods Enzymol. 1997;283:313-22. No abstract available.

PMID:
9251029
47.

Uncoupling of DNA replication and cell cycle progression by human cyclin E.

Mumberg D, Haas K, Möröy T, Niedenthal R, Hegemann JH, Funk M, Müller R.

Oncogene. 1996 Dec 5;13(11):2493-7.

PMID:
8957094
48.

Unique tumor antigens redefined as mutant tumor-specific antigens.

Mumberg D, Wick M, Schreiber H.

Semin Immunol. 1996 Oct;8(5):289-93. Review.

PMID:
8956457
49.
50.

Structure of the human TIMP-3 gene and its cell cycle-regulated promoter.

Wick M, Härönen R, Mumberg D, Bürger C, Olsen BR, Budarf ML, Apte SS, Müller R.

Biochem J. 1995 Oct 15;311 ( Pt 2):549-54.

Supplemental Content

Loading ...
Support Center